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Background/aim: Antinuclear antibodies (ANA) and antimitochondrial antibodies (AMA) have essential markers for the diagnosis of
autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). These autoantibodies are detecting different laboratory methods.
In this study, we studied the diagnostic performance of used methods in detecting ANA and AMA.
Materials and methods: The autoantibody profiles of patients with AIH and PBC groups were analyzed with the indirect
immunofluorescence test (IIF) and liver-specific antigens containing immunoblot test (IB).
Results: There were 45 (87%) women in the study group and 8 (53%) women in the control group. The mean age of the patients was
50.5 ± 14.21 years old. The serum ALT and AST levels were higher in AIH, and ALP, GGT, and Ig M were higher in PBC. IIF test results
among AIH/PBC groups; there was no difference in overall ANA positivity (p: 0.078). AMA was negative in all patients with AIH but
positive in 83.3% of patients with PBC. IB test results among AIH/PBC groups; antibodies against PDGH, LKM-1, and Scl-70 were not
observed in any patient with AIH/PBC. Except for M2 (p: 0.001) and M23E (p: 0.007) antibodies, there was no significant difference
in antibodies between groups. Out of five PBC patients with negative AMA by IIF method, one was positive for AMA-M2, two were
positive anti-gp210, and three were positive anti-M2-3E, but anti-sp100 was negative in all of them by the IB.
Conclusions: AIH/PBC has complex associations with different autoantibodies, and some of these antibodies are not readily detected
by the IIF test. IB assays with a wide variety of liver-specific antigens may be helpful in the diagnosis (especially in patients with AMA
negative PBC) and follow-up in AIH/PBC patients.
Key words: Autoimmune hepatitis, primary biliary cholangitis, immunofluorescence test, immunoblot test

1. Introduction
Autoimmune liver diseases (AILD) are a group of chronic
inflammatory liver diseases, namely autoimmune hepatitis
(AIH), primary biliary cholangitis (PBC), primary sclerosing
cholangitis (PSC), and overlap syndrome (AIH associated
with PBC or PSC) [1,2]. The etiology of AILD has not yet
been described clearly; however, immunological mechanisms
have been accused primarily in the pathogenesis of the
disease. AILD can start at any age, and their diagnosis is based
on clinical, radiological, histopathological, and serological
investigations. Varieties of autoantibodies play significant
roles in the diagnosis and classification of AILD. The level and
presence of specific autoantibodies can also give information
about the prognosis and response to the treatment. Therefore,
autoantibody profiles in AILD are essential components of
the diagnosis and follow-up of these diseases [2–7].

Indirect immunofluorescence assay (IIF) is the
most commonly used screening technique to search
for autoantibodies. Since there are problems in
autoantibody detection and interpretation at routine
serology laboratories, the usage of other methods, such as
immunoblot tests (IB) together with IIF, may be helpful for
accurate analysis of autoantibodies [8–10].
This study aimed to evaluate the diagnostic and
prognostic value of IIF assay and IB test in AIH/PBC by
focusing on the value of liver-specific autoantibodies
measured by IB.
2. Material and methods
2.1. Study population
The ethics committee approved the study of Hacettepe
University Hospitals, a tertiary-care hospital in Ankara,
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Turkey (study no: GO16/414). After the written informed
consent was taken, 52 patients with the initial diagnosis of
AIH/PBC/overlap syndrome (19 of AIH, 31 of PBC, and 2
of overlap syndrome) and 15 controls who have dyspepsia
without other disease were included. AIH, PBC, and
overlap syndrome were diagnosed according to the Paris
criteria [11,12]. The liver biopsies were performed in all
patients to confirm the diagnosis and make the differential
diagnosis
2.2. Exclusion criteria
The exclusion criteria were malignancies, severe
cardiopulmonary or renal failure, diabetes mellitus,
rheumatologic diseases such as systemic lupus
erythematosus, rheumatoid arthritis, scleroderma, or
ankylosing spondylitis, decompensated cirrhosis, and
concomitant other chronic liver diseases including
nonalcoholic steatohepatitis, alcoholic hepatitis, hepatitis
C virus infection (HCV), hepatitis B virus infection
(HBV), Wilson’s disease, or hemochromatosis. Since the
role of autoantibodies in the diagnosis of PSC is minor,
patients with PSC were also excluded from this study.
2.3. Laboratory investigation
The serum samples were collected for serological
tests and laboratory workup, including complete blood
count, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), gamma-glutamyl transferase
(GGT), alkaline phosphatase (ALP), albumin, total
protein, total bilirubin, immunoglobulin (Ig)G, IgM
serum levels and prothrombin time (INR).
The antinuclear antibody (ANA), antismooth-muscle
antibody (ASMA), antiliver-kidney microsome type
1 antibody (LKM1), and antimitochondrial antibody
(AMA) were analyzed by IIF microscopy (Euroimmun
AG, Germany). The substrate combination consisting of
human epithelial cells (HEp-2) and primate liver was used
for the determination of ANA, and samples with serum
titers ≥ 1:160 are considered positive. AMA, ASMA,
and LKM were determined by using the basic mosaic
profile containing HEp-2 cells, rat kidney-stomach-liver
cells as substrates were according to the manufacturer’s
recommendation. Both patients and controls were also
screened by EUROLINE Profile Autoimmune Liver
Diseases 14 Ag immunoblot strips (Euroimmun AG,
Germany) the automated EURO Line Scan according to
the manufacturer’s recommendation. This test kit contains
strips coated with 14 different liver-specific antigens:
AMA-M2, M2-3E, Sp100, PML, gp210, LKM-1, LC-1,
SLA/LP, SS-A, Ro-52, Scl-70, CENP A, CENP B, and
PDGH.
2.4. Statistical analysis
Statistical analyses were performed by using the statistical
package SPSS 20.0. The statistical test applied was
Fisher’s M-test for percentages, chi-square analysis for
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nonparametric variables, Mann–Whitney U-test for
unpaired data, and nonparametric Wilcoxon’s-test for
paired data. P-values <0.05 were considered statistically
significant.
3. Results
There were 45 (87%) women in the study group and 8
(53%) women in the control group. The mean age of the
patients was 50.5 ± 14.21 years old. As there were only
two patients with overlap syndrome, they were evaluated
separately. Nineteen patients with AIH and 31 patients
with PBC were compared with each other. The baseline
characteristics of the AIH/PBC patients are demonstrated
in Table 1. The serum levels of bilirubin, albumin, IgG were
similar among groups (p > 0.05), but ALT, AST was higher
in AIH, and ALP, GGT, and Ig M were higher in PBC.
The distribution of each autoantibody by IIF among
AIH/PBC groups is demonstrated in Table 2. There was
no difference in overall ANA positivity (p: 0.078). AMA
was negative in all patients with AIH but positive in 83.3%
of patients with PBC. The ASMA was positive only in one
patient with AIH, while LKM was negative in all study
patients.
The distribution of each autoantibody by IB among
AIH/PBC groups is demonstrated in Table 3. Antibodies
against PDGH, LKM-1, and Scl-70 were not observed
in any patient with AIH/PBC. Except for M2 (p: 0.001)
and M23E (p: 0.007) antibodies, there was no significant
difference in antibodies between groups. All patients with
anti-SLA antibodies were also positive for anti-Ro-52
antibodies. There was no significant difference in antigp210 antibodies between groups, but all PBC patients
with positive anti-gp210 antibodies had 5- or 6-fold
increased liver enzymes and 2- or 3-fold increased IgM
levels, and they were more resistant to treatment.
Out of five PBC patients with negative AMA by IIF
method, one was positive for AMA-M2, two were positive
anti-gp210, and three were positive anti-M2-3E, but antisp100 was negative in all of them by the IB.
When serum samples of the control group as analyzed
by IB for 14 different liver-specific antigens, all of the
antibodies were negative in all of them, except for 4
(26.6%) controls having M2-3E positivity.
According to the Paris criteria, two of our patients
were compatible with overlap syndrome [11,12]. The
characteristics of the first patient were as follows: A
39-year-old female had been referred to us due to elevated
liver enzymes, ALT 288 U/l (5–40), AST 176 U/l (8–33),
GGT 230 U/l (5–40), ALP 796 U/l (91–258) and bilirubin
was normal, Serum IgG was 3420 mg/dL (700–1600), and
IgM was 313 mg/dL (40–230). Other hepatitis etiologies
were negative, and autoimmune serology showed ANA and
AMA positive. Her liver biopsy showed some cholestatic
and hepatic features together.
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Table 1. The baseline characteristics of the patients.
Study population
(n: 50)

OİH
(n: 19)

PBC
(n: 31)

P

Age (median)

51 (21–73)

46 (21–62)

52 (25–73)

0.20

Gender (M/F)

5/45

2/17

3/28

0.92

ALT
(median/min-max)

50 (8–864)

88 (8–864)

36(11–121)

0.009*

AST(
median/min-max)

45 (12–1198)

64(12–1198)

35(18–102)

0.03*

ALP
(median/min-max)

141 (56–991)

95(56–178)

188(96–991)

< 0.001*

GGT
(median/min-max)

98.5 (11–570)

70(11–220)

135(11–570)

0.01*

T. bil
(median/min-max)

0.75 (0.3–4.47)

0.73(0.3–2.81)

0.85(0.38–4.47)

0.55

D. bil
(median/min-max)

0.2 (0.1–1.3)

0.3(0.1–1.3)

0.18(0.1–0.76)

0.86

ALB
(median/min-max)

4.18 (2.5–4.9)

4.2(2.6–4.9)

4.17(2.5–4.7)

0.81

Ig G
(median/min-max)

1580 (834–4700)

1660(836–4700)

1545(834–3300)

0.20

Ig M
(median/min-max)

236 (58–1290)

172(58–268)

290.5(85–1290)

0.001*

* p < 0.05
Table 2. IIF assay results among AIH and PBC patients.
Study population
(n: 50)

AIH
(n: 19)

PBC
(n: 31)

ANA
(ANA unknown in three patients with AIH)

40/47(85.1%)

15/16 (93.7%)

25/31 (80.6%)

AMA
(AMA unknown in five patients with AIH and 1 PBS)

25/44(56.8%)

0/14

25/30 (83.3%)

ASMA

1/50 (0.5%)

1(5.5)

0

LKM

0

0

0

The characteristics of the second patient were as
follows: A 58-year-old female patient presented to us with
ALT 341 U/l (5–40), AST 150 U/l (8–33), GGT 1796 U/l
(5–40), ALP 668 U/l (91–258) and bilirubin was normal.
The serum IgG was 3640 mg/dL (700–1600), and IgM
was 420 mg/dL (40–230). Other hepatitis etiologies were
negative, and autoimmune serology showed ANA and
AMA positive. Her liver biopsy showed some cholestatic
and hepatic features together too. The distribution of

each autoantibody by IB among two patients with overlap
syndrome was PML which was positive only in the first
patient, and Sp100 was positive in the second patient.
Interestingly, all other antibodies were found negative in
both.
4. Discussion
The serological detection of autoantibodies for AIH/PBC
practice was done in clinical by various assays such as IIF
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Table 3. Immunoblot assay results among AIH and PBC patients.
Study population
(n: 50)

AIH (%)
(n: 19)

PBC (%)
(n: 31)

Control (%)
(n: 15)

CB

4

5.3

3.2

0

CA

2

0

3.2

0

Scl-70

0

0

0

0

Ro52

36

31.6

38.7

0

SS-A

22

26.3

19.4

0

SLA/LP

8

10.5

6.5

0

LC-1

8

10.5

6.5

0

Gp210

26

26.3

25.8

0

PML

14

5.3

19.4

0

Sp100

12

5.3

16.1

0

M2

40

10.5

58.1*

0

M23E

74

52.6

87.1*

26.6

LKM-1

0

0

0

0

PDGH

0

0

0

0

*p < 0.05

test, IB assay, double-dimension immune-diffusion test
(DID), counter-immune-electrophoresis (CİE), enzymelinked immunosorbent assay (ELISA) (enzyme immune
assay (EIA), line-immuno-assay (LIA) and radio-immuneprecipitation assay (RIA) [1,2,7,11]. In this study, the
performances of the IIF test and IB assay were evaluated
for the diagnosis of AIH/PBC.
The IAHG guideline in 2004 concluded that the IIF test
should be the first-line screening method in all patients
who are considered to have AILD and so be investigated
for ANA, AMA, SMA, and anti-LKM [13]. Consistently,
the IIF test is the most commonly used screening technique
for searching autoantibody [2,3]. IF detects full AMA as a
pattern, and it detects AMA and ANA altogether. IIF is
the standard gold method for the determination of ANA
[13]. On the other hand, IF also has some limitations, such
as labor-intensive technical steps and interpretation errors
[12].
IB differs with respect to the number and type of
included preselected mitochondrial antigens. While some
include PDH-E2 as a sole antigen, the others include three
or even more antigens among PDH E1-2-3, 2-oxoglutarate
dehydrogenase (OGDC-E2), and branched-chain 2-oxoacid dehydrogenase (BCOADC-E2). The main advantages
of IB are that it is less operator-dependent and more
automated. However, it also has limitations, such as factors
related to commercial kits, the inclusion of a limited
number of preselected antigen(s), or in a particular case
presence of undefined antigens other than M2 [12–18].
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AMA is an accurate diagnostic marker for PBC and can
easily be detected by using the IIF method [15–18]. There
are nine subtypes of AMA, but only four of them, namely
anti-M2, anti-M4, anti-M8, and anti-M9, are associated
with PBC [17]. The anti-M2-3E antibody is a subunit of the
anti-M2 antibody. Despite the fact that IIF is considered
a sensitive and specific test in the diagnosis of PBC,
false positivity may occur due to other autoantibodies.
Anti-M2 and anti-M2-3E antibodies are the most specific
and sensitive autoantibodies for PBC [18–20]. In our
study, AMA was positive in 83% of PBC patients by IIF
test, while anti-M2 antibody and anti-M2-3E antibody
positivity were significantly higher, and they were detected
respectively at 58% and 87% by IB assay. However, antiM2-3E antibody positivity can also be detected at a lower
rate in healthy people, as shown in Pang et al.’s study [21]
and the control group of 26.6% of our study.
AMA can be negative in PBC patients with clinical
and histopathological findings of PBC [11,12]. In a study
[20] including 127 PBC patients, AMA was negative in 36
patients by IIF test; however, eight patients were positive
by enzyme immune assay (EIA), and 16 patients were antiM2-3E antibody positive by IB assay. In our study, PBC
patients with negative AMA by IIF method had positive
60% M2-3E antibodies by IB assay. Thus, we concluded
that the determination of the anti-M2-3E antibody
increases the diagnostic accuracy of AMA among PBC
patients. Therefore, anti-M2-3E should be evaluated in
patients with clinical suspension for PBC. However, more
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studies are needed on anti-M2-3E antibodies in AMAnegative PBC patients.
The dual presence of anti-Ro52 and anti-SLA was
reported in patients with AIH [19]. Antibodies to Ro/
SSA and anti-SLA are not cross-reactive to each other
and are related with HLA DRB1_03. This dual presence of
anti-SLA and anti-Ro/SSA may explain this shared HLA
association [18]. Patients with dual antibody positivity had
more severe PBC, more advanced histological features,
and higher serum bilirubin levels than negative patients.
These antibodies were also associated with relapse after
corticosteroid withdrawal in AIH and PBC [18,19]. In our
study, anti-Ro52 antibodies were positive approximately
30% of patients with AIH, 40% of patients with PBC. A
study by Montana-Loza et al. [22], including 170 patients
with AIH-type 1, revealed that anti-Ro-52 was present
in 38.2% of patients, while anti-SLA was positive in only
15.8% in whom 15.2% of them had concomitant positivity
for both antibodies. In another study, Saıto et al. [9]
reported the concomitant presence of anti–SLA and antiRo-52 antibodies among patients with AILD. They also
reported that the presence of anti-Ro-52 antibodies was
found to be related to the severity of the disease, but in
our study, we did not show such a relationship. As in other
studies [18,19], we observed that all PBC patients with
positive anti-SLA antibodies were also positive for antiRo-52 antibodies.
Anti-sp100 antibody can be a valuable serologic marker
to confirm the diagnosis, especially in AMA-negative PBC
patients with typical clinic or laboratory findings [23–24].
In our study, the anti-Sp 100 antibody was positive in 16%
of PBC patients while negative in all AMA-negative PBC
patients. Our study used a line immunoblot assay to detect
liver-specific autoantibodies. However, the diagnostic
method used in Mickiewicz P [25] and Manuel Lucena J
[26] was ELISA. Thus, the differences might be attributed
to different diagnostic methods used or to the different
demographic characteristics of the patient groups.
Anti-gp210 is positive in approximately 25% of
patients with PBC with up to 97% specificity [27,28].
Some studies showed that anti-gp210 antibodies in PBC
patients indicated a poor prognosis with unfavorable
disease course and rapid progression. Therefore, antigp210 antibodies are useful for monitoring treatment
efficacy and early determination of patients who are
at high risk for hepatic failure [29]. In our study, PBC
patients with anti-gp210 antibody positivity had higher
liver enzymes and a poor prognosis despite the treatment.

Thus, anti-gp210 antibodies may have the potential to
become an important prognostic marker in PBC patients
[30–32]. Autoantibodies against 3-PHGDH were reported
to be positive at 68.3% in AIH, 15.6% in PBC, 12.8% in
chronic hepatitis C, 9.8% in chronic hepatitis B, and 2.5%
in controls [10]. Yoshida et al. proposed that 3-PHGDH
was not associated with the development of AILD [33].
We did not detect any autoantibodies against 3-PHGDH
in healthy and AILD patients.
5. Conclusion
Numerous autoantibodies can be used for the diagnosis
of patients with AIH/PBC. AIH/PBC has complex
associations to different autoantibodies, and some of these
antibodies are not readily detected by the IIF test. However,
autoantibody titers and the detectability of antibodies can
change according to the method and laboratories or even
during diseases. IB assays with a wide variety of liverspecific antigens should be considered in the diagnostic
portfolio of a laboratory, and these antibodies can be
used to monitor the course of the disease and provide
information about its prognosis.
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